data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+Español
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+Italiano
data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+Français
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
TScan Therapeutics
(NASDAQ:TCRX)
$3.145
0.045[1.45%]
At close: Jun 30
$2.66
-0.4850[-15.42%]
After Hours: 9:09AM EDT
Day High/Low3.09 - 3.26
52 Week High/Low1.6 - 14.71
Open / Close3.13 / 3.15
Float / Outstanding16.3M / 24M
Vol / Avg.26.1K / 105.4K
Mkt Cap75.6M
P/E-
50d Avg. Price2.75
Div / Yield-
Payout Ratio-
EPS-0.67
Total Float16.3M

TScan Therapeutics (NASDAQ:TCRX), Quotes and News Summary

TScan Therapeutics (NASDAQ: TCRX)

Day High/Low3.09 - 3.26
52 Week High/Low1.6 - 14.71
Open / Close3.13 / 3.15
Float / Outstanding16.3M / 24M
Vol / Avg.26.1K / 105.4K
Mkt Cap75.6M
P/E-
50d Avg. Price2.75
Div / Yield-
Payout Ratio-
EPS-0.67
Total Float16.3M
Benzinga - Jun 23, 2022, 4:25AM
Benzinga - May 31, 2022, 7:05AM
Benzinga - May 10, 2022, 8:12AM
Benzinga - May 9, 2022, 7:20AM
Benzinga - Mar 9, 2022, 7:09AM
Benzinga - Jan 24, 2022, 12:30PM
Benzinga - Jan 24, 2022, 7:05AM
Benzinga - Dec 16, 2021, 6:15AM
Benzinga - Dec 13, 2021, 9:20AM
Benzinga - Nov 10, 2021, 7:15AM
Benzinga - Sep 28, 2021, 7:26AM
load more
Sector: Health Care.Industry: Biotechnology
TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-18
REV
Q1 2022Est.ActualSurprise
EPS-0.670
REV3.021M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

TScan Therapeutics Questions & Answers

Q
How do I buy TScan Therapeutics (TCRX) stock?
A

You can purchase shares of TScan Therapeutics (NASDAQ: TCRX) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are TScan Therapeutics's (TCRX) competitors?
Q
What is the target price for TScan Therapeutics (TCRX) stock?
A

The latest price target for TScan Therapeutics (NASDAQ: TCRX) was reported by HC Wainwright & Co. on Tuesday, May 10, 2022. The analyst firm set a price target for 15.00 expecting TCRX to rise to within 12 months (a possible 376.95% upside). 5 analyst firms have reported ratings in the last year.

Q
Current Stock Price for TScan Therapeutics (TCRX)?
A

The stock price for TScan Therapeutics (NASDAQ: TCRX) is $3.145 last updated June 30, 2022, 8:00 PM UTC.

Q
Does TScan Therapeutics (TCRX) pay a dividend?
A

A quarterly cash dividend of $0.42 per share of Class A Common Stock. The quarterly cash dividend was payable on June 30, 2018 to stockholders of record on June 14, 2018.

Q
When is TScan Therapeutics (NASDAQ:TCRX) reporting earnings?
A

TScan Therapeutics’s Q2 earnings are confirmed for Thursday, August 18, 2022.

Q
Is TScan Therapeutics (TCRX) going to split?
A

There is no upcoming split for TScan Therapeutics.

Q
What sector and industry does TScan Therapeutics (TCRX) operate in?
A

TScan Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.